Lilly and Novo Nordisk’s battle for weight loss drugs reaches pharmacies

Weight loss drug Zepbound gains ground in the US against Novo Nordisk’s Wegovy. Lilly has about 40% market share in the U.S., reaching 130,000 prescriptions in the week ending July 19, compared to Wegovy’s 200,000, according to IQVIA data.

Compartir esta publicacion:

ENTRADAS POPULARES
SÍGANOS
Danos like en facebook
Síganos en Twitter
Suscríbase a nuestro canal
Tik Tok
TRANSMISIÓN EN VIVO